ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 広島大学の刊行物
  2. Hiroshima Journal of Medical Sciences
  3. 44巻4号

Cisplatin-Based Neoadjuvant Chemotherapy for Invasive Bladder Cancer

https://hiroshima.repo.nii.ac.jp/records/2013379
https://hiroshima.repo.nii.ac.jp/records/2013379
fe15b745-09c9-4b7d-bd40-661b5b541e3a
名前 / ファイル ライセンス アクション
HiroshimaJMedSci_44_129.pdf HiroshimaJMedSci_44_129.pdf (374.3 KB)
Item type デフォルトアイテムタイプ_(フル)(1)
公開日 2023-03-18
タイトル
タイトル Cisplatin-Based Neoadjuvant Chemotherapy for Invasive Bladder Cancer
言語 en
作成者 Kadena, Hitoshi

× Kadena, Hitoshi

en Kadena, Hitoshi

Search repository
Igawa, Mikio

× Igawa, Mikio

en Igawa, Mikio

Search repository
Shigeta, Masanobu

× Shigeta, Masanobu

en Shigeta, Masanobu

Search repository
Nakamoto, Takahisa

× Nakamoto, Takahisa

en Nakamoto, Takahisa

Search repository
Usui, Tsuguru

× Usui, Tsuguru

en Usui, Tsuguru

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
主題
主題Scheme Other
主題 Invasive bladder cancer
主題
主題Scheme Other
主題 Neoadjuvant chemotherapy
主題
主題Scheme Other
主題 Cisplatin
主題
主題Scheme NDC
主題 490
内容記述
内容記述 Between February 1988 and March 1993, 24 patients with locally advanced bladder cancer (stages T2-4N0-3M0) were included in this study. Combination chemotherapy consisting of methotrexate, vinblastine, epirubicin (doxorubicin) and cisplatin (M-VAC) was given to the patients in a neoadjuvant setting.   The clinical stage was T2N0M0 in eight patients, T3aN0M0 in three, T3bN0M0 in seven, T4N0M0 in five and T4N3M0 in one. After chemotherapy, total cystectomy was performed in 20 patients and partial cystectomy 4. Of 24 patients, one (4%) showed a pathological complete response, and eight (33%) had a pathological partial response, for an overall response rate of 38% (95% confidence limits 20 to 57%). Nine patients who achieved a pathological response to chemotherapy had a significantly higher survival rate than the nonresponders (p<0.01). In the relationship between the clinical stage and the response to chemotherapy, clinical T2 and T3a diseases were more likely to respond to chemotherapy than clinical T3b and T4 diseases, with a response rate of 64% and 15%, respectively. While a positive relationship between the pathological response and survival was observed, adequate follow-up is needed to assess the ability of neoadjuvant chemotherapy to improve the prognosis of patients with locally advanced bladder cancer.
言語 en
出版者
出版者 Hiroshima University Medical Press
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ departmental bulletin paper
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 0018-2052
収録物識別子
収録物識別子タイプ NCID
収録物識別子 AA00664312
開始ページ
開始ページ 129
書誌情報 Hiroshima Journal of Medical Sciences
Hiroshima Journal of Medical Sciences

巻 44, 号 4, p. 129-132, 発行日 1995-12
旧ID 37872
戻る
0
views
See details
Views

Versions

Ver.1 2025-02-23 06:31:39.307667
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3